Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine Mepesuccinate and Azacitidine in High Grade MDS
NCT03564873Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Sep 2018
- Primary completion
- Oct 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Colorado Denver. Started Sep 2018; status: active, not recruiting.
02
Drugs
homoharringtonine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03564873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564873.